Name: Capital Market Publishers India Pvt. Ltd.
Telephone: 91-22-25229720

LOGIN HERE

Cancel

BSE Code : 543444 | NSE Symbol : | ISIN : INE0DRT01018 | Industry : Pharmaceuticals - Indian - Bulk Drugs & Formln |

Board Meeting

Announcement Date	Date Of Meeting	Purpose	Detail
20-Jun-2025	20-Jun-2025	Change in Other Executives	The Appointment of CS Anand Katarmal as Company Secretary and Compliance Officer of the Company w.e.f. June 20, 2025.
26-May-2025	29-May-2025	Accounts	Fabino Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 inter alia to consider and approve 1. The Audited Financial Results (Standalone) for the half year and year ended March 31 2025. 2. The Audited Financial Results (Consolidated) for the half year and year ended March 31 2025. 3. The Appointment of M/s. JNG & Co. LLP (Firm Registration Number L2024MH017500) Practicing Company Secretaries as the Secretarial Auditor of the Company for F.Y. 2025-26 and 2026-27. 4. The Appointment of M/s. B B Gusani and Associates (Firm Registration Number 140785W) Chartered Accountants as the Internal Auditor of the Company for F.Y. 2025-26 and 2026-27. 5. Any other matter with the permission of the Chair. 1. The Audited Standalone Financial Results set out in compliance with Accounting Standards for the Half year and year ended March 31, 2025 together with Statement of Assets & Liabilities and Cash Flow Statement. 2. The Audited Consolidated Financial Results set out in compliance with Accounting Standards for the Half year and year ended March 31, 2025 together with Statement of Assets & Liabilities and Cash Flow Statement. 3. The Appointment of M/s. JNG & Co. LLP (Firm Registration Number L2024MH017500), Practicing Company Secretaries, as the Secretarial Auditor of the Company for F.Y. 2025-26 and 2026-27. 4. The Appointment of M/s. B B Gusani and Associates (Firm Registration Number 140785W), Chartered Accountants as the Internal Auditor of the Company for F.Y. 2025-26 and 2026-27. 5. The Acceptance of Resignation of Ms. Kanchi Gehlot as Company Secretary and Compliance Officer of the Company with effect from May 29, 2025 (As per BSE Announcement Dated on 29/05/2025)
17-Mar-2025	17-Mar-2025	Change in Directors	With reference to above subject matter and in pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors the Company at their meeting held today i.e. March 17, 2025 at Registered Office of the Company, inter alia considered the following; 1. Appointment of Mr. Nitin Mehra (DIN: 08142337) as Additional (Executive) Director designated as Executive Director subject to approval of shareholders of the Company in the ensuing General Meeting of the Company. 2. Acceptance of resignation of Mr. Jitender Kumar (DIN: 10057415).
16-Oct-2024	21-Oct-2024	Half Yearly Results	Fabino Enterprises Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 21/10/2024 inter alia to consider and approve Intimation of Board Meeting for Consideration and Approval of Unaudited Financial Results (standalone and consolidated) for half year ended September 2024. Outcome of Board Meeting & Submission of Unaudited Financial Results for Half Year ended September 30, 2024 (As per BSE Announcement Dated on 21/10/2024)
22-Aug-2024	22-Aug-2024	Change in Directors	Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, and on the recommendation of Nomination and Remuneration committee , the Board of Directors of the Company at their meeting held on August 22, 2024 has inter alia, considered and approved the following business as attached
17-May-2024	28-May-2024	Accounts	Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 28/05/2024 inter alia to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Tuesday May 28 2024 at Registered Office of the Company to discuss and approve the Audited Financial Results (standalone and consolidated) for Half Year And Year Ended March 31 2024 thereon and any other business with permission of Chair. In continuation of our letter dated May 17, 2024, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 28th May 2024, inter alia considered and approved as attached. Read less.. In continuation of our letter dated May 17, 2024, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 28th May 2024, inter alia considered and approved as attached. Read less.. (As Per BSE Announcement Dated on 28.05.2024)
27-Feb-2024	27-Feb-2024	Postal Ballot	Pursuant to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 27th February, 2024, inter alia approved as attached.
26-Dec-2023	26-Dec-2023	Change in Directors	The Board of Directors of the Company at their meeting held on 26th December, 2023 has inter alia, considered and approved as attached.
02-Nov-2023	13-Nov-2023	Quarterly Results	Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/11/2023 inter alia to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Friday November 10 2023 at Registered Office of the Company at Jeevan Vihar Extension Near Shubham Garden Murthal Road Sonipat Haryana-131001 inter-alia to discuss and approve among other items the Unaudited Financial Results and Statement of Assets and Liabilities for Half Year ended September 30 2023. Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 13/11/2023 ,inter alia, to consider and approve In continuation of our letter dated November 02, 2023, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, it was intimated that the meeting scheduled to be held on November 10th, 2023, now stands adjourned due to non-availability of Directors and the Chairman with the consent of all the directors/members present at the meeting hereby decided to adjourn the Meeting on November 13, 2023 (As per BSE Announcement Dated on 10/11/2023) Outcome of Financial results for the Half-yearly ended September 2023 In continuation of our letter dated November 02, 2023 and November 10, 2023, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Board of Directors the Company at their meeting held today i.e. November 13, 2023 at Registered Office of the Company, inter alia considered and approved the following; 1. The Unaudited Standalone Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30, 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow. 2. The Unaudited Consolidated Financial Results set out in compliance with Accounting Standards (AS) for the Quarter and Half Year ended September 30, 2023 together with Statement of Assets and Liabilities and Statement of Cash Flow. (As Per BSE Announcement Dated on 13/11/2023)
17-May-2023	30-May-2023	Accounts	Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2023 inter alia to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Wednesday May 24 2023 at Registered Office of the Company at 105 Plot No 12 Barodia Tower 1st Floor D Block Central Market Prashant Vihar New Delhi- 110085 inter-alia to discuss and approve among other items the Audited Financial Results and Statement of Assets and Liabilities for Half Year and Financial Year ended March 31 2023. Further in terms of the Code of Conduct of Company adopted under SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the securities of the Company is already closed and shall open 48 hours after conclusion of the Board Meeting. Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2023 ,inter alia, to consider and approve In continuation of our letter dated May 17, 2023, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the meeting scheduled to be held on 24th May, now stands adjourned due to non-availability of Directors and the meeting will now be held on Tuesday, May 30, 2023 at Registered Office of the Company at 105, Plot No 12, Barodia Tower, 1st Floor, D Block, Central Market, Prashant Vihar, New Delhi- 110085, inter-alia to discuss and approve, among other items, the Audited Financial Results and Statement of Assets and Liabilities for Half Year and Financial Year ended March 31, 2023 (As per BSE Announcement Dated on 24/05/2023) In continuation of our letter dated May 17, 2023, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 30th May 2023, inter alia considered and approved as attached. (As Per BSE Announcement Dated on 30.05.2023)
02-May-2023	02-May-2023	Change in Other Executives	The Board of Directors of the Company at their meeting held today i.e. 02nd May, 2023 has inter alia, considered and approved the following: 1. Acceptance of Resignation of CS Aslam Mohammed as Company Secretary and Compliance Officer of the Company. 2. Appointment of CS Kanchi Gehlot as Company Secretary and Compliance Officer of the Company w.e.f. May 02, 2023. The disclosure pursuant to point 2 of Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 is enclosed as Annexure A. The meeting of Board of Directors commenced at 4.30 P.M and concluded at 05:00 P.M. Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that, Board has appointed in its meeting held today CS Kanchi Gehlot as Company Secretary and Compliance Officer w.e.f May 02, 2023 in replacement of CS Aslam Mohammed. The disclosure pursuant to Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 is enclosed as Annexure A. Pursuant to requirement under Regulation 30(5) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 the contact details of the Key Managerial Personnel ('KMP') who have being authorized by Board of Directors of the Company, for the purpose of determining materiality of an event or information, is enclosed with this letter. (As Per BSE Announcement Dated on 02.05.2023)
02-Nov-2022	09-Nov-2022	Half Yearly Results	Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 09/11/2022 inter alia to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015 this is to inform you that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Wednesday November 09 2022 at Registered Office of the Company at 105 Plot No 12 Barodia Tower 1st Floor D Block Central Market Prashant Vihar New Delhi-110085 inter-alia to discuss and approve among other items the Unaudited Financial Results and Statement of Assets and Liabilities for half year ended September 30 2022. Further in terms of the Code of Conduct of Company adopted under SEBI (Prohibition of Insider Trading) Regulations 2015 the trading window for dealing in the securities of the Company is already closed and shall open 48 hours after conclusion of the Board Meeting. In continuation of our letter dated November 02, 2022, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2022 , duly approved by the Board of Directors of the Company in their meeting held today i.e. November 09, 2022 together with Statement of Assets and Liabilities, Cash Flow and Limited Review Report thereon are enclosed. (As Per BSE Announcement Dated on 09/11/2022) In continuation of our letter dated November 02, 2022, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Unaudited Financial Results set out in compliance with Accounting Standards (AS) for the Half Year ended September 30, 2022 , duly approved by the Board of Directors of the Company in their meeting held on November 09, 2022 together with Statement of Assets and Liabilities, Cash Flow and Limited Review Report thereon are enclosed. (As Per BSE Announcement Dated on 24/11/2022)
12-Aug-2022	12-Aug-2022	Change in Other Executives	Pursuant to Regulation 30 read with Schedule III of the SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015, we wish to inform you that, Board has appointed in its meeting held today CS Aslam Mohammad as Company Secretary and Compliance Officer w.e.f August 11, 2022 in replacement of CS Jeel Poshiya. The disclosure pursuant to Regulation 30 read with Schedule III of SEBI (LODR) Regulations, 2015 is enclosed as Annexure A.
17-May-2022	24-May-2022	Accounts	Audited Results Fabino Life Sciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 24/05/2022 ,inter alia, to consider and approve In pursuant to Regulation 29(1) of SEBI (Listing Obligation and Disclosure Requirements) Regulations, 2015 this is to inform you, that a meeting of the Board of Directors of Fabino Life Sciences Limited is scheduled to be held on Tuesday, May 24, 2022 at Registered Office of the Company at 105, Plot No 12, Barodia Tower, 1st Floor, D Block, Central Market, Prashant Vihar, New Delhi- 110085, inter-alia to discuss and approve, among other items, the Audited Financial Results and Statement of Assets and Liabilities for Half Year and Financial Year Ended March 31, 2022. Further, in terms of the Code of Conduct of Company adopted under SEBI (Prohibition of Insider Trading) Regulations, 2015 the trading window for dealing in the securities of the Company is already closed and shall open 48 hours after conclusion of the Board Meeting. Kindly acknowledge and oblige. In continuation of our letter dated May 17, 2022, pursuant to regulation 33 read with Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements ) Regulations, 2015, we hereby inform you that the Board of Directors of the Company in its meeting held on 24th May 2022, inter alia considered and approved the following; 1. Submission of Audited Financial Results for Half Year and Year ended March 31, 2022. 2. Appointment of M/s. B B Gusani And Associates (FRN: 140785W) as Internal Auditors of the Company for the F.Y. 2022-23. 3. Appointment of M/s. JNG & CO. Practicing Company Secretaries as Secretarial Auditors of the Company for the F.Y. 2022-23. 4. Appointment of Mr.Sumit Malik (DIN: 09615815) as an Additional Director of the Company with immediate effect and shall hold office till conclusion of upcoming General Meeting. He is not debarred from holding the office of Director by virtue of any order of SEBI or any other such authority. Dear Sir/Madam, With reference to the above captioned subject, we wish to inform you that the Board of Directors of the Company at their meeting held today i.e. Tuesday, May 24, 2022 interalia considered the Appointment of Mr. Sumit Malik (DIN: 09615815) as an Additional Director (Non-Executive) of the Company with immediate effect and shall hold office till conclusion of upcoming General Meeting He is not debarred from holding the office of Director by virtue of any order of SEBI or any other such authority. Please find attached the brief profile of Mr. Sumit Malik, enclosed as Annexure A. Kindly acknowledge the receipt of the same and oblige. (As per BSE Announcement Dated on 24/5/2022)

LOGIN HERE

Fabino Enterprises Ltd

Board Meeting